PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1988 June; 81(6): 1675–1681.
PMCID: PMC442610

Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.

Abstract

It is known that the ingestion of glucose alone causes a greater increase in plasma glucose levels than ingestion of the same amount of glucose given with other nutrients. Since physiological plasma concentrations of cholecystokinin (CCK) prolong gastric emptying, it is proposed that after a meal, CCK may modify plasma glucose levels by delaying glucose delivery to the duodenum. To evaluate the effect of CCK on oral glucose tolerance, plasma CCK, insulin, and glucose levels and gastric emptying rates were measured in eight normal males before and after the ingestion of 60 g glucose with the simultaneous infusion of either saline or one of two doses of CCK-8 (12 or 24 pmol/kg per h). Gastric emptying rates were measured by gamma camera scintigraphy of technetium 99m sulfur colloid and plasma CCK levels were measured by a sensitive and specific bioassay. Basal CCK levels averaged 1.0 +/- 0.1 pM (mean +/- SEM, n = 8) and increased to 7.1 +/- 1.1 pM after a mixed liquid meal. After glucose ingestion, but without CCK infusion, CCK levels did not change from basal, and the gastric emptying t1/2 was 68 +/- 3 min. Plasma glucose levels increased from basal levels of 91 +/- 3.9 mg/dl to peak levels of 162 +/- 11 mg/dl and insulin levels increased from 10.7 +/- 1.8 microU/ml to peak levels of 58 +/- 11 microU/ml. After glucose ingestion, with CCK infused at 24 pmol/kg per h, plasma CCK levels increased to 8 pM and the gastric emptying t1/2 increased to 148 +/- 16 min. In concert with this delay in gastric emptying, peak glucose levels rose to only 129 +/- 17 mg% and peak insulin levels rose to only 24.2 +/- 4.2 microU/ml. With CCK at 12 pmol/kg per h, similar but less dramatic changes were seen. To demonstrate that endogenous CCK could modify the plasma glucose and insulin responses to oral glucose, oral glucose was given with 50 g of lipid containing long-chain triglycerides. This lipid increased peak CCK levels to 3.7 +/- 0.9 pM. Concomitant with this rise in CCK was a delay in gastric emptying and a lowering of plasma glucose and insulin values. To confirm that CCK reduced hyperglycemia by its effect on gastric motility, 36 g glucose was perfused directly into the duodenum through a nasal-duodenal feeding tube in four subjects. With duodenal perfusion of glucose, there was no change in plasma CCK levels, but plasma glucose levels increased from basal levels of 93+/-5 to 148+/-6 mg/dl and insulin levels rose from 10.6+/-3.5 to 29.5+/-5.2 microU/ml. When CCK was infused at 24 pmol/kg per h, neither the plasma glucose nor insulin responses to the duodenal administration of glucose were modified. Thus we conclude that CCK, in physiological concentrations, delays gastric emptying, slows the delivery of glucose to the duodenum, and reduces postprandial hyperglycemia. These data indicate, therefore, that CCK has a significant role in regulating glucose homeostasis in human.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Unger RH, Ketterer H, Dupré J, Eisentraut AM. The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest. 1967 Apr;46(4):630–645. [PMC free article] [PubMed]
  • Dupre J, Curtis JD, Unger RH, Waddell RW, Beck JC. Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest. 1969 Apr;48(4):745–757. [PMC free article] [PubMed]
  • Otsuki M, Sakamoto C, Yuu H, Maeda M, Morita S, Ohki A, Kobayashi N, Terashi K, Okano K, Baba S. Discrepancies between the doses of cholecystokinin or caerulein-stimulating exocrine and endocrine responses in perfused isolated rat pancreas. J Clin Invest. 1979 Mar;63(3):478–484. [PMC free article] [PubMed]
  • Szecówka J, Lins PE, Efendić S. Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats. Endocrinology. 1982 Apr;110(4):1268–1272. [PubMed]
  • Hermansen K. Effects of cholecystokinin (CCK)-4, nonsulfated CCK-8, and sulfated CCK-8 on pancreatic somatostatin, insulin, and glucagon secretion in the dog: studies in vitro. Endocrinology. 1984 May;114(5):1770–1775. [PubMed]
  • Verspohl EJ, Ammon HP, Williams JA, Goldfine ID. Evidence that cholecystokinin interacts with specific receptors and regulates insulin release in isolated rat islets of Langerhans. Diabetes. 1986 Jan;35(1):38–43. [PubMed]
  • Liddle RA, Goldfine ID, Williams JA. Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology. 1984 Sep;87(3):542–549. [PubMed]
  • Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest. 1985 Apr;75(4):1144–1152. [PMC free article] [PubMed]
  • Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA. Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. J Clin Endocrinol Metab. 1987 Sep;65(3):395–401. [PubMed]
  • Hunt JN, Stubbs DF. The volume and energy content of meals as determinants of gastric emptying. J Physiol. 1975 Feb;245(1):209–225. [PubMed]
  • Barker GR, Cochrane GM, Corbett GA, Dufton JF, Hunt JN, Roberts SK. Glucose, glycine and diglycine in test meals at stimuli to a duodenal osmoreceptor slowing gastric emptying. J Physiol. 1978 Oct;283:341–346. [PubMed]
  • Bateman DN. Effects of meal temperature and volume on the emptying of liquid from the human stomach. J Physiol. 1982 Oct;331:461–467. [PubMed]
  • Hunt JN. Does calcium mediate slowing of gastric emptying by fat in humans? Am J Physiol. 1983 Jan;244(1):G89–G94. [PubMed]
  • Yamagishi T, Debas HT. Cholecystokinin inhibits gastric emptying by acting on both proximal stomach and pylorus. Am J Physiol. 1978 Apr;234(4):E375–E378. [PubMed]
  • Moran TH, McHugh PR. Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol. 1982 May;242(5):R491–R497. [PubMed]
  • Anika MS. Effects of cholecystokinin and caerulein on gastric emptying. Eur J Pharmacol. 1982 Nov 19;85(2):195–199. [PubMed]
  • Liddle RA, Morita ET, Conrad CK, Williams JA. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest. 1986 Mar;77(3):992–996. [PMC free article] [PubMed]
  • Rabinowitz D, Merimee TJ, Maffezzoli R, Burgess JA. Patterns of hormonal release after glucose, protein, and glucose plus protein. Lancet. 1966 Aug 27;2(7461):454–456. [PubMed]
  • Bantle JP, Laine DC, Castle GW, Thomas JW, Hoogwerf BJ, Goetz FC. Postprandial glucose and insulin responses to meals containing different carbohydrates in normal and diabetic subjects. N Engl J Med. 1983 Jul 7;309(1):7–12. [PubMed]
  • Christian PE, Datz FL, Sorenson JA, Taylor A. Technical factors in gastric emptying studies. J Nucl Med. 1983 Mar;24(3):264–268. [PubMed]
  • Bondar RJ, Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem. 1974 May;20(5):586–590. [PubMed]
  • Solomon TE, Yamada T, Elashoff J, Wood J, Beglinger C. Bioactivity of cholecystokinin analogues: CCK-8 is not more potent than CCK-33. Am J Physiol. 1984 Jul;247(1 Pt 1):G105–G111. [PubMed]
  • Liddle RA, Elashoff J, Reeve JR., Jr Relative bioactivities of cholecystokinins-8 and -33 on rat pancreatic acini. Peptides. 1986 Sep-Oct;7(5):723–727. [PubMed]
  • Harper AA, Raper HS. Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine. J Physiol. 1943 Jun 30;102(1):115–125. [PubMed]
  • Levant JA, Kun TL, Jachna J, Sturdevant RA, Isenberg JI. The effects of graded doses of C-terminal octapeptide of cholecystokinin on small intestinal transit time in man. Am J Dig Dis. 1974 Mar;19(3):207–209. [PubMed]
  • Eysselein VE, Reeve JR, Jr, Shively JE, Hawke D, Walsh JH. Partial structure of a large canine cholecystokinin (CCK58): amino acid sequence. Peptides. 1982 Jul-Aug;3(4):687–691. [PubMed]
  • Mutt V, Jorpes JE. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem. 1968 Oct 17;6(1):156–162. [PubMed]
  • Eng J, Du BH, Pan YC, Chang M, Hulmes JD, Yalow RS. Purification and sequencing of a rat intestinal 22 amino acid C-terminal CCK fragment. Peptides. 1984 Nov-Dec;5(6):1203–1206. [PubMed]
  • Rehfeld JF. Immunochemical studies on cholecystokinin. I. Development of sequence-specific radioimmunoassays for porcine triacontatriapeptide cholecystokinin. J Biol Chem. 1978 Jun 10;253(11):4016–4021. [PubMed]
  • MCINTYRE N, HOLDSWORTH CD, TURNER DS. NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE. Lancet. 1964 Jul 4;2(7349):20–21. [PubMed]
  • Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia. 1985 Aug;28(8):565–573. [PubMed]
  • Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973 Nov;37(5):826–828. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation